Cover Image
市場調查報告書

Azilect(帕金森氏症治療藥):市場預測與分析

Azilect (Parkinson's Disease) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 217326
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
Azilect(帕金森氏症治療藥):市場預測與分析 Azilect (Parkinson's Disease) - Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 61 Pages
簡介

Azilect(rasagiline)是第二代的MAO-B抑制劑,是Teva Pharmaceuticals所開發的帕金森氏症治療藥。Azilect已通過早期階段帕金森氏症的單劑治療藥(1日1次,1mg),以及左旋多巴的輔助性治療(1日1次,配合需要0.5∼1mg)(Azilect package insert, 2012)藥認証。

本報告提供帕金森氏症的治療藥之一──Azilect的全球市場相關分析,提供疾病概要和治療方法,競爭的企業·藥品概要,市場競爭概況,Azilect的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
    • QoL(生活品質)
  • 症狀

第4章 疾病管理

  • 概要
    • 診斷:The UK Brain Bank的評估標準
    • 治療指南與主要的處方藥
  • 治療方法概要
    • 多巴胺有作用之等級
    • 帕金森氏症的各階段治療方法
    • 其他治療選擇
  • 帕金森氏症的評估規模
    • 帕金森氏症統一規模(UPDRS)
    • Hoehn and Yahr的病期分類
    • 其他臨床評估方法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:MAO-B抑制劑

第6章 關於Azilect(rasagiline)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 未來預測

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC396DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Azilect (rasagiline) is a second-generation MAO-B inhibitor, developed by Teva Pharmaceuticals for the treatment of the signs and symptoms of Parkinson's disease. Azilect is approved for use as a monotherapy in early Parkinson's disease at a once-daily dosage of 1mg, or as an adjunctive therapy to levodopa at 0.5mg or 1mg, as needed, once daily (Azilect package insert, 2012).

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Azilect including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Azilect for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Azilect performance
  • Obtain sales forecast for Azilect from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Brazil).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - MAO-B Inhibitors

6. Azilect (rasagiline)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Parkinson's Disease Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Compliance Assumptions
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Product Profile - Azilect
  • Table 11: Azilect SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Azilect, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
Back to Top